Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $2,875,200.00 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the sale, the chief executive officer owned 194,309 shares in the company, valued at approximately $18,622,574.56. This represents a 13.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Peetz also recently made the following trade(s):

• On Monday, March 16th, Christopher Peetz sold 40,985 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $91.98, for a total transaction of $3,769,800.30.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $92.49 on Friday. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $43.50 and a fifty-two week high of $114.99. The firm’s 50-day simple moving average is $97.22 and its 200 day simple moving average is $90.22. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28. The stock has a market cap of $5.64 billion, a P/E ratio of -6.80 and a beta of 0.50.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The company had revenue of $159.88 million for the quarter, compared to the consensus estimate of $148.21 million. Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. Mirum Pharmaceuticals’s revenue for the quarter was up 43.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.30) earnings per share. Equities analysts expect that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of MIRM. Comerica Bank boosted its position in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares during the period. AQR Capital Management LLC boosted its position in shares of Mirum Pharmaceuticals by 307.3% in the 1st quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock valued at $2,211,000 after purchasing an additional 37,028 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Mirum Pharmaceuticals by 7.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock valued at $1,176,000 after purchasing an additional 1,720 shares during the period. Caxton Associates LLP acquired a new position in shares of Mirum Pharmaceuticals in the 1st quarter valued at $217,000. Finally, Empowered Funds LLC boosted its position in shares of Mirum Pharmaceuticals by 15.4% in the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock valued at $1,729,000 after purchasing an additional 5,120 shares during the period.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on MIRM. Wall Street Zen lowered Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings lowered Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Raymond James Financial reaffirmed a “strong-buy” rating and set a $165.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. HC Wainwright set a $185.00 target price on Mirum Pharmaceuticals in a report on Thursday, May 7th. Finally, Royal Bank Of Canada lifted their target price on Mirum Pharmaceuticals from $128.00 to $142.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $137.64.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.